<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430625</url>
  </required_header>
  <id_info>
    <org_study_id>TKT032</org_study_id>
    <nct_id>NCT00430625</nct_id>
  </id_info>
  <brief_title>A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group, Two-Dose Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme
      glucocerebrosidase (GCB). Due to this deficiency of functional GCB, glucocerebroside
      accumulates within macrophages leading to cellular engorgement, organomegaly, and organ
      system dysfunction. The purpose of this study is to evaluate the efficacy of every other week
      dosing of Gene-Activated® Human Glucocerebrosidase (GA-GCB, velaglucerase alfa) at doses of
      45 and 60 U/kg in treatment-naïve patients with type 1 Gaucher disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 Gaucher disease, the most common form, accounts for more than 90% of all cases and
      does not involve the Central Nervous System (CNS). Typical manifestations of type 1 Gaucher
      disease include hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia,
      hypermetabolism, skeletal pathology, growth retardation, pulmonary disease, and decreased
      quality of life. Gene-Activated® human glucocerebrosidase (GA-GCB; velaglucerase alfa) is
      produced in a continuous human cell line using proprietary gene-activation technology and has
      an identical amino acid sequence to the naturally occurring human enzyme. Velaglucerase alfa
      contains terminal mannose residues that target the enzyme to the macrophages-the primary
      target cells in Gaucher disease. This study was designed to determine the efficacy, safety
      and pharmacokinetics of GA-GCB in men, women, and children with Type 1 Gaucher disease. Each
      patients duration of treatment was 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group.</measure>
    <time_frame>Week 53</time_frame>
    <description>Efficacy endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Months in Hemoglobin Concentration in 45 U/kg Treatment Group</measure>
    <time_frame>Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Months in Platelet Counts for Each Treatment Group.</measure>
    <time_frame>Week 53</time_frame>
    <description>intent to treat (ITT) Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Months in Normalized Liver Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Week 51</time_frame>
    <description>Liver Volume has been normalized for percentage of body weight for each treatment arm. Liver size relative to body weight = (Liver volume [cc]/Body weight [kg])*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Months in Normalized Spleen Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI))</measure>
    <time_frame>Week 51</time_frame>
    <description>12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population. Spleen Volume has been normalized for percent of body weight for each treatment arm. Spleen size relative to body weight = (Spleen volume [cc]/Body weight [kg])*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to 12 Months in Plasma Chitotriosidase for Each Treatment Group</measure>
    <time_frame>Week 53</time_frame>
    <description>Percent Change from Baseline to Weeks 53 by Randomized velaglucerase alfa Treatment Group - Subset of intent to treat (ITT) Population who were wild type homozygous for chitotriosidase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to 12 Months in Chemokine (C-C Motif) Ligand 18 (CCL18)</measure>
    <time_frame>Week 53</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Gaucher Disease, Type 1</condition>
  <arm_group>
    <arm_group_label>VPRIV®-45 U/kg, IV, every other week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VPRIV®-60 U/kg, IV, every other week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase,GA-GCB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VPRIV ®,</intervention_name>
    <description>Intravenous (IV) infusion, every other week via intravenous infusion for 12 months</description>
    <arm_group_label>VPRIV®-45 U/kg, IV, every other week</arm_group_label>
    <arm_group_label>VPRIV®-60 U/kg, IV, every other week</arm_group_label>
    <other_name>VPRIV®</other_name>
    <other_name>velaglucerase alfa</other_name>
    <other_name>GA-GCB</other_name>
    <other_name>Gene-activated® human glucocerebrosidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has a documented diagnosis of type 1 Gaucher disease, as determined by
             deficient glucocerebrosidase (GCB) activity relative to normal as measured in
             leukocytes or by genotype analysis and is willing and able to provide written informed
             consent prior to initiating any study-related procedures

          -  Patient is at least 2 years of age

          -  Patient has Gaucher disease-related anemia and

          -  Patient has at least moderate splenomegaly or

          -  Patient has Gaucher disease-related thrombocytopenia or

          -  Patient has a readily palpable enlarged liver

          -  Patient has not received treatment for Gaucher disease within 30 months prior to study
             entry

          -  Female patients of child-bearing potential agree to use a medically acceptable method
             of contraception. Male patients must agree to use a medically acceptable method of
             birth control.

          -  Patient must be sufficiently cooperative to participate in the study as judged by the
             Investigator.

        Exclusion Criteria:

        Includes:

          -  Patient has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher
             disease

          -  Patient is antibody-positive to imiglucerase during screening or has experienced an
             anaphylactic reaction to imiglucerase

          -  Patient has received treatment with any investigational drug or device within the 30
             days prior to study entry

          -  Patient is Human immunodeficiency virus (HIV) positive

          -  Patient is hepatitis positive

          -  Patient presents with iron, folic acid and/or vitamin B12 deficiency sustained anemia
             during screening

          -  Patient, patient's parent(s), or patient's legal guardian(s) is/are unable to
             understand the nature, scope, and possible consequences of the study

          -  Patient has a significant comorbidity(ies)that might affect study data or confound the
             study results

          -  Patient is a pregnant and/or lactating female

          -  Patient is unable to comply with the protocol or is unlikely to complete the study, as
             determined by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiran Bhirangi, M.D., FRCS</last_name>
    <role>Study Director</role>
    <affiliation>Shire Human Genetic Therapies, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ari Zimran, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Derlis Emilio Gonzalez Rodriguez, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sociedad Espanola de Socorros Mutuos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Francoise Ben Dridi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Rabta Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isaac Kisinovsky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hipolito Yrigoyen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena A. Lukina, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Center for Haematology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hipolito Yrigoyen</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedad Espanola de Socorros Mutuos</name>
      <address>
        <city>Asuncion</city>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Center for Haematology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Rabta Hospital</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Israel</country>
    <country>Paraguay</country>
    <country>Russian Federation</country>
    <country>Tunisia</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.vpriv.com/</url>
    <description>Shire product Information web site</description>
  </link>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2007</study_first_submitted>
  <study_first_submitted_qc>February 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2007</study_first_posted>
  <results_first_submitted>June 3, 2010</results_first_submitted>
  <results_first_submitted_qc>August 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 10, 2010</results_first_posted>
  <last_update_submitted>February 19, 2014</last_update_submitted>
  <last_update_submitted_qc>February 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VPRIV®</keyword>
  <keyword>Enzyme Replacement Therapy</keyword>
  <keyword>Gaucher disease</keyword>
  <keyword>glucocerebrosidase</keyword>
  <keyword>beta-glucocerebrosidase</keyword>
  <keyword>Acid beta-glucocerebrosidase</keyword>
  <keyword>glucosylceramidase</keyword>
  <keyword>D-glucosyl-N-acylsphingosine glucohydrolase</keyword>
  <keyword>gene activation</keyword>
  <keyword>human</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Type 1 Gaucher disease patients (pts) &gt;2 years. The first patient (pt) consented to participate in the study on 11 January 2007 and the last patient enrolled on 04 April 2008.</recruitment_details>
      <pre_assignment_details>Gaucher disease-related anemia and at least 1 of the following: moderate splenomegaly, thrombocytopenia or palpable enlarged liver. Patients were not to have received any treatment for Gaucher disease within 30 months of study entry. Patients randomized to receive VPRIV®(45 or 60 U/kg)every other week by intravenous (IV) infusion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>VPRIV® (45 U/kg, IV, Every Other Week)</title>
          <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
        </group>
        <group group_id="P2">
          <title>VPRIV® (60 U/kg, IV, Every Other Week)</title>
          <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VPRIV® (45 U/kg, IV, Every Other Week)</title>
          <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
        </group>
        <group group_id="B2">
          <title>VPRIV® (60 U/kg, IV, Every Other Week)</title>
          <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.0" spread="16.75" lower_limit="6" upper_limit="62"/>
                    <measurement group_id="B2" value="23.5" spread="11.77" lower_limit="4" upper_limit="42"/>
                    <measurement group_id="B3" value="25" spread="15.28" lower_limit="4" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Paraguay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tunisia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Spleen volume</title>
          <description>Normal spleen volume is defined as 0.2 percentage of body weight.</description>
          <units>Percent of body weight</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" lower_limit="0.5" upper_limit="13.0"/>
                    <measurement group_id="B2" value="2.8" lower_limit="0.4" upper_limit="7.4"/>
                    <measurement group_id="B3" value="2.9" lower_limit="0.4" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline hemoglobin concentration per treatment group</title>
          <description>Modified baseline used for analysis (defined as average of screening and baseline values)</description>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.90" spread="1.278" lower_limit="8.45" upper_limit="12.85"/>
                    <measurement group_id="B2" value="10.83" spread="1.272" lower_limit="7.05" upper_limit="12.25"/>
                    <measurement group_id="B3" value="10.85" spread="1.248" lower_limit="7.05" upper_limit="12.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline liver volume</title>
          <description>Normal liver volume is defined as 2.5 percent of body weight.</description>
          <units>Percent of body weight</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.50" lower_limit="2.3" upper_limit="7.2"/>
                    <measurement group_id="B2" value="3.65" lower_limit="2.4" upper_limit="8.0"/>
                    <measurement group_id="B3" value="3.5" lower_limit="2.3" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline platelet counts per treatment group</title>
          <description>Modified baseline used for analysis (defined as average of screening and baseline values)</description>
          <units>(x10^9/L)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.00" spread="59.56" lower_limit="13" upper_limit="264"/>
                    <measurement group_id="B2" value="66.75" spread="111.91" lower_limit="47" upper_limit="438"/>
                    <measurement group_id="B3" value="65.5" spread="86.71" lower_limit="13" upper_limit="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group.</title>
        <description>Efficacy endpoint</description>
        <time_frame>Week 53</time_frame>
        <population>12 patients in the 60 U/kg group were analyzed for efficacy in the intent to treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>VPRIV® (60 U/kg, IV, Every Other Week)</title>
            <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group.</title>
          <description>Efficacy endpoint</description>
          <population>12 patients in the 60 U/kg group were analyzed for efficacy in the intent to treat (ITT) population.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.429" lower_limit="1.717" upper_limit="3.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary endpoint was based solely on the 60 U/kg treatment arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>paired t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.429</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.324</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.717</ci_lower_limit>
            <ci_upper_limit>3.141</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Months in Hemoglobin Concentration in 45 U/kg Treatment Group</title>
        <time_frame>Week 53</time_frame>
        <population>13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>VPRIV® (45 U/kg, IV, Every Other Week)</title>
            <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Months in Hemoglobin Concentration in 45 U/kg Treatment Group</title>
          <population>13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population.</population>
          <units>(g/dL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.438" lower_limit="1.488" upper_limit="3.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Months in Platelet Counts for Each Treatment Group.</title>
        <description>intent to treat (ITT) Population</description>
        <time_frame>Week 53</time_frame>
        <population>12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>VPRIV® (45 U/kg, IV, Every Other Week)</title>
            <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
          </group>
          <group group_id="O2">
            <title>VPRIV® (60 U/kg, IV, Every Other Week)</title>
            <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Months in Platelet Counts for Each Treatment Group.</title>
          <description>intent to treat (ITT) Population</description>
          <population>12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population.</population>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.92" lower_limit="11.20" upper_limit="70.64"/>
                    <measurement group_id="O2" value="50.88" lower_limit="23.97" upper_limit="77.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Months in Normalized Liver Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI)</title>
        <description>Liver Volume has been normalized for percentage of body weight for each treatment arm. Liver size relative to body weight = (Liver volume [cc]/Body weight [kg])*100</description>
        <time_frame>Week 51</time_frame>
        <population>12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>VPRIV® (45 U/kg, IV, Every Other Week)</title>
            <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
          </group>
          <group group_id="O2">
            <title>VPRIV® (60 U/kg, IV, Every Other Week)</title>
            <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Months in Normalized Liver Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI)</title>
          <description>Liver Volume has been normalized for percentage of body weight for each treatment arm. Liver size relative to body weight = (Liver volume [cc]/Body weight [kg])*100</description>
          <population>12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population.</population>
          <units>Percent body weight</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" lower_limit="-0.92" upper_limit="0.32"/>
                    <measurement group_id="O2" value="-0.84" lower_limit="-1.58" upper_limit="-0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Months in Normalized Spleen Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI))</title>
        <description>12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population. Spleen Volume has been normalized for percent of body weight for each treatment arm. Spleen size relative to body weight = (Spleen volume [cc]/Body weight [kg])*100</description>
        <time_frame>Week 51</time_frame>
        <population>12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>VPRIV® (45 U/kg, IV, Every Other Week)</title>
            <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
          </group>
          <group group_id="O2">
            <title>VPRIV® (60 U/kg, IV, Every Other Week)</title>
            <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Months in Normalized Spleen Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI))</title>
          <description>12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population. Spleen Volume has been normalized for percent of body weight for each treatment arm. Spleen size relative to body weight = (Spleen volume [cc]/Body weight [kg])*100</description>
          <population>12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population.</population>
          <units>Percent body weight</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" lower_limit="-3.17" upper_limit="-0.57"/>
                    <measurement group_id="O2" value="-1.92" lower_limit="-3.04" upper_limit="-0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to 12 Months in Plasma Chitotriosidase for Each Treatment Group</title>
        <description>Percent Change from Baseline to Weeks 53 by Randomized velaglucerase alfa Treatment Group - Subset of intent to treat (ITT) Population who were wild type homozygous for chitotriosidase.</description>
        <time_frame>Week 53</time_frame>
        <population>2 patients in the 60 U/kg group and 7 patients in the 45 U/kg group who were wild type for the chitotriosidase mutation were analyzed; remaining patients were deficient in chitotriosidase activity.</population>
        <group_list>
          <group group_id="O1">
            <title>VPRIV® (45 U/kg, IV, Every Other Week)</title>
            <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
          </group>
          <group group_id="O2">
            <title>VPRIV® (60 U/kg, IV, Every Other Week)</title>
            <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to 12 Months in Plasma Chitotriosidase for Each Treatment Group</title>
          <description>Percent Change from Baseline to Weeks 53 by Randomized velaglucerase alfa Treatment Group - Subset of intent to treat (ITT) Population who were wild type homozygous for chitotriosidase.</description>
          <population>2 patients in the 60 U/kg group and 7 patients in the 45 U/kg group who were wild type for the chitotriosidase mutation were analyzed; remaining patients were deficient in chitotriosidase activity.</population>
          <units>Percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.16" spread="7.768"/>
                    <measurement group_id="O2" value="-69.65" spread="17.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to 12 Months in Chemokine (C-C Motif) Ligand 18 (CCL18)</title>
        <time_frame>Week 53</time_frame>
        <population>12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>VPRIV® (45 U/kg, IV, Every Other Week)</title>
            <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
          </group>
          <group group_id="O2">
            <title>VPRIV® (60 U/kg, IV, Every Other Week)</title>
            <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to 12 Months in Chemokine (C-C Motif) Ligand 18 (CCL18)</title>
          <population>12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed.</population>
          <units>Percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.76" spread="7.623"/>
                    <measurement group_id="O2" value="-66.02" spread="5.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored either from time of informed consent/assent (Amendment 1) or from the first infusion (original protocol) through 30 days after the last infusion (Week 53).</time_frame>
      <desc>Adverse events may have been discovered through observation/examination of the patient, questioning of the patient or complaint by the patient. Adverse Events could have included unexpected laboratory values that became significantly out of range. Other adverse events were determined to be possibly/probably related to VPRIV by the Investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>VPRIV® (45 U/kg, IV, Every Other Week)</title>
          <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
        </group>
        <group group_id="E2">
          <title>VPRIV® (60 U/kg, IV, Every Other Week)</title>
          <description>velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <description>Considered not related by investigator.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperproteinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Shire’s agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial’s multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to small sample sizes no conclusions could be drawn on Quality of life (QOL).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Tiffany Crump</name_or_title>
      <organization>Shire Human Genetic Therapies (Shire HGT)</organization>
      <phone>484-595-8850</phone>
      <email>tcrump@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

